Industry Satellite Symposia webcasts #ESMOAsia22

Watch the webcasts from our industry partners' Satellite Symposia.

Updates on the strategy of treatment in pancreatic cancer in Asia
Teresa Macarulla
Treatment strategy for metastatic pancreatic ductal adenocarcinoma: Surgeon’s point of view
Sohei Satoi
Japanese real-world data of Nal-IRI+5-FU/LV and the impact of UGT1A1 polymorphisms on treatment outcomes
Kazuaki Harada
Role of Nal-IRI in second-line treatment: Japanese oncologist’s perspective
Masafumi Ikeda
Conclusion and Q&A

Welcome and introduction
Christian Jackisch
Transforming the experience of patients with HER2+ BC with recent clinical trials of PH FDC SC
Shu Wang
Value of subcutaneous treatment options for the healthcare system: Introducing flexible care an opportunity to bring treatment closer to patients
Christian Jackisch
NCCS homecare: Delivering cancer care at home
Elaine Lim
Question & answers
Closing remarks
Christian Jackisch

Welcome and opening
Hwai Loong Kong
Current management of NSCLC in Asia Pacific
Thanyanan Baisamut (reungwetwattana)
What’s new in management of non-mutated NSCLC
Solange Peters
Defining optimal sequencing in HCC with evidence and experience-based discussion
Han Chong Toh
How can we further optimize the management of RCC patients
Marniza Binti Saad
Q&A and closing
Hwai Loong Kong, Solange Peters

Opening remarks
Ross Soo
Setting out the sail in advanced NSCLC: The role of comprehensive genomic testing in advanced NSCLC
Timothy Tay
Watching out for the tsunami: The burden of unmet need in advanced NSCLC patients with EGFR exon 20 insertion mutations
Ross Soo
Adjusting the sails in advanced NSCLC management: Treatment options for advanced NSCLC patients with EGFR exon 20 insertion mutations
Byoung Chul Cho
Panel discussion
Closing remarks
Ross Soo

Welcome and introduction
Alvin Wong
Treating la/mUC: Unmet needs and the rapidly evolving landscape
Alvin Wong
Spotlight on the clinical value of enfortumab vedotin in la/mUC: A review of the EV-301 core data
Thomas Powles
Patient management strategies for la/mUC treatment with enfortumab vedotin: A clinical case discussion
Terence Friedlander
Panel discussion / Q&A
Chair's summary: Identifying the right patient for enfortumab vedotin
Alvin Wong

Watch session

Welcome and introduction
Stephen Liu
How can precision medicine and biomarkers testing improve patient journey?
Angela Takano
Evolving landscape of early-stage lung cancer treatment: IMpower010
Stephen Liu
Navigating options for mNSCLC
Ross Soo
Molecular tumors boards: Navigating through the complexity
Jee Hyun Kim
Panel discussion and Q&A
Meeting close
Jee Hyun Kim

Welcome and introduction
Matthew Chau Hsien Ng
Immunotherapeutic advances in the treatment of colorectal cancer
Takayuki Yoshino
Update on immuno-oncology for the treatment of gastric cancer
Taroh Satoh
Advances in immuno-oncology for esophageal cancer: First-line metastatic disease and earlier stages
Chih-Hung Hsu
Q&A and summary
Close
Matthew Chau Hsien Ng

Welcome and introduction
Laurence Albiges
Assessment of the MIUC treatment landscape in 2022
Laurence Albiges
Evidence for use of immuno-oncology in the perioperative setting
Yiping Zhu
Integrating immuno-oncology approaches in the early MIUC treatment pathway
Eiji Kikuchi
Interactive multidisciplinary team meeting
Q&A
Summary and close
Laurence Albiges

Table of Contents